Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction

2020 ◽  
Vol 23 (7) ◽  
pp. 880-881
Author(s):  
Keisuke Kaneishi ◽  
Kengo Imai ◽  
Kazunori Nishimura ◽  
Norio Sakurai ◽  
Hiroyuki Kohara ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Bowel Obstruction ◽  
Nausea And Vomiting ◽  
Malignant Bowel Obstruction ◽  
Advanced Cancer Patients

Can malignant bowel obstruction in advanced cancer patients be treated at home?

2010 ◽  
Vol 19 (3) ◽  
pp. 431-433 ◽  
Author(s):  
Giampiero Porzio ◽  
Federica Aielli ◽  
Lucilla Verna ◽  
Brigida Galletti ◽  
Ghazaleh Shoja e Razavi ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Bowel Obstruction ◽  
Malignant Bowel Obstruction ◽  
Advanced Cancer Patients ◽  
At Home

Use of parenteral nutrition in patients with advanced cancer

2008 ◽  
Vol 33 (1) ◽  
pp. 102-106 ◽  
Author(s):  
Isaac Soo ◽  
Leah Gramlich
Keyword(s):  
Parenteral Nutrition ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Bowel Obstruction ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Intestinal Failure ◽  
Advanced Cancer Patients ◽  
End Stage ◽  
Northern Alberta

The purpose of this study is to describe patient-related variables in a cohort of advanced cancer patients (ACPs) enrolled in a home parenteral nutrition (HPN) program. This study reviewed the cohort of ACPs enrolled in the Northern Alberta Home Total Parenteral Nutrition Program (NAHTPNP). Thirty-eight ACPs received HPN during the study period, 24% of all patients admitted for PN. Of these, 27 (71%) were female. Mean age was 48.76 y (SD 13.8 y). Bowel obstruction was the most common indication for initiating HPN (84%, 32) and ovarian cancer was the most common malignancy (34%, 13). Patients who began HPN with a Karnofsky performance status (KPS) of greater than 50 (median of 70) were found to have a longer duration of life (median: 6 months) compared with patients who began HPN with a KPS of 50 or below (median = 50; median 3 months; p = 0.01; two-tailed). There was no difference in survival between malignancy type (p = NS). Advanced cancer is the fastest growing indication for enrollment in the HPN program. ACP demonstrated a 3% average annual increase proportionate to all indications for HPN starts, accounting for 7%–48% of HPN starts from 1999–2006. HPN is an increasingly used therapy for patients with advanced cancer, most commonly for intestinal failure in the setting of bowel obstruction. Initiation of HPN at a higher KPS was associated with a longer duration of life. Further studies are needed to validate the use of TPN in end-stage cancer patients.

Radiographic and Clinical Factors Associated with Improved Outcomes in Advanced Cancer Patients with Bowel Obstruction

2011 ◽  
Vol 14 (9) ◽  
pp. 990-996 ◽  
Author(s):  
Brian D. Badgwell ◽  
Carlo Contreras ◽  
Robert Askew ◽  
Robert Krouse ◽  
Barry Feig ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Bowel Obstruction ◽  
Clinical Factors ◽  
Advanced Cancer Patients ◽  
Factors Associated ◽  
Improved Outcomes
Sign in / Sign up

Export Citation Format

Share Document